This article is more than 5 years old. Information may no longer be current.

B&L to buy anti-infective from InSite Vision

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch & Lomb has agreed to buy an ocular infective drug that is in development from InSite Vision, the companies announced last week in a joint press release.

Under terms of the agreement, InSite Vision will receive a cash payment, reimbursement of development costs associated with ISV-403 and a percentage of future sales of the product in all licensed countries.

ISV-403 is in development for the treatment of ocular infections. The drug candidate combines a fluoroquinolone licensed from Japan’s SSP Co. Ltd. with InSite’s patented drug delivery system, DuraSite. Preclinical studies indicate the drug is effective against bacteria resistant to earlier fluoroquinolone products, according to the joint press release. A phase 1 study in normal volunteers was started earlier this year.